- GlobeNewswire•7 days agoRedHill Biopharma Announces Allowance of a Patent in Japan Supporting RHB-104 for Multiple Sclerosis
RedHill has received from the Japan Patent Office a Notice of Allowance for a new patent covering RHB-104 for multiple sclerosis, expected to be valid until 2032, once granted RedHill’ s robust RHB-104 ...
- GlobeNewswire•12 days ago
TEL-AVIV, Israel, Oct. 13, 2016-- RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small ...
- Insider Monkey•17 days ago
RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) just announced the initiation of the latest element of its Yeliva development program, and the company has teed up for a number of near term catalysts on the back of the study. It’s a phase II targeting hepatocellular carcinoma (HCC), which is the most common primary malignant cancer of […]
RedHill Biopharma Ltd. (RDHL)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Day's Range||13.60 - 13.75|
|52wk Range||8.10 - 16.54|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-7.64|
|Avg Vol (3m)||39,939|
|Dividend & Yield||N/A (N/A)|